Lindbrook Capital’s Avidity Biosciences RNAM Stock Holding History

Lindbrook Capital’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$16.7K	Buy	566 +26	+5%	+$810	﹤0.01%	1433
2024 Q4	$15.7K	Sell	540 -69	-11%	-$2.88K	﹤0.01%	1422
2024 Q3	$28K	Buy	609 +18	+3%	+$781	﹤0.01%	1106
2024 Q2	$24.1K	Buy	591 +89	+18%	+$2.55K	﹤0.01%	1132
2024 Q1	$12.8K	Hold	502	–	–	﹤0.01%	1432
2023 Q4	$4.54K	Buy	502 +15	+3%	+$100	﹤0.01%	1933
2023 Q3	$3.11K	Buy	487 +329	+208%	+$2.83K	﹤0.01%	1967
2023 Q2	$1.75K	Buy	158 +19	+14%	+$238	﹤0.01%	2201
2023 Q1	$2.13K	Sell	139 -9	-6%	-$198	﹤0.01%	2218
2022 Q4	$3.28K	Buy	148 +132	+825%	+$1.97K	﹤0.01%	2010
2022 Q3	$0	Hold	16	–	–	﹤0.01%	2869
2022 Q2	$0	Sell	16 -236	-94%	-$3.51K	﹤0.01%	2724
2022 Q1	$5K	Buy	+252	New	+$4.28K	﹤0.01%	1609

Other funds holding RNAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lindbrook Capital's RNAM Position: Q1 2025 in Review

Lindbrook Capital increased its Avidity Biosciences (RNAM) stake by 4.8% in Q1 2025, buying an estimated $810 and bringing the position to 566 shares worth $16.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1433.

Lindbrook Capital first reported a position in RNAM in Q1 2022 and has held it in 13 quarters since. The position peaked at $28K in Q3 2024. 220 funds tracked by Wall St. Rank hold RNAM as of Q1 2025.

Lindbrook Capital held 566 shares of Avidity Biosciences worth $16.7K as of Q1 2025.
Lindbrook Capital bought 26 Avidity Biosciences shares in Q1 2025, an estimated $810.
Avidity Biosciences made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1433 holding.
Lindbrook Capital first reported a position in Avidity Biosciences in Q1 2022 and has held it in 13 quarters since.
Lindbrook Capital's Avidity Biosciences position peaked at $28K in Q3 2024.
220 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.